Aurinia Early Urinary Protein Reduction Predicts Response
Ключові слова
Анотація
Опис
Voclosporin is a next generation CNI intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current development program is to investigate whether voclosporin added to the standard of care treatment in active LN is able to reduce disease activity, as measured by a reduction in proteinuria.The background therapy will be MMF 2 g daily, initial treatment with IV methylprednisolone followed by a reducing course of oral corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.
Дати
| Востаннє перевірено: | 08/31/2017 |
| Перший поданий: | 10/25/2016 |
| Орієнтовна реєстрація подана: | 10/26/2016 |
| Опубліковано вперше: | 10/30/2016 |
| Останнє оновлення надіслано: | 09/17/2017 |
| Останнє оновлення опубліковано: | 09/19/2017 |
| Фактична дата початку навчання: | 05/31/2015 |
| Розрахункова дата первинного завершення: | 11/30/2016 |
| Розрахункова дата завершення дослідження: | 02/16/2017 |
Стан або захворювання
Втручання / лікування
Drug: Voclosporin
Фаза
Групи рук
| Рука | Втручання / лікування |
|---|---|
| Experimental: Voclosporin Voclosporin, oral, 23.7 mg BID | Drug: Voclosporin |
Критерії прийнятності
| Вік, придатний для навчання | 18 Years До 18 Years |
| Стать, яка підходить для вивчення | All |
| Приймає здорових добровольців | Так |
| Критерії | Key Inclusion Criteria: - Diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria (1997; see Appendix 6). - Kidney biopsy within 24 months prior to screening with a histologic diagnosis of lupus nephritis International Society of Nephrology/Renal Pathology Society Classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in combination with Class III or IV. - Laboratory evidence of active nephritis at screening, defined as: Class III, IV-S or Class IV-G (proteinuria ≥1000 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of ≥1.0 mg/mg assessed in a first morning void urine specimen). Class V, alone or in combination with Class III or IV, (proteinuria ≥1,500 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of ≥1.5 mg/mg assessed in a first morning void urine specimen). Key Exclusion Criteria: - Estimated glomerular filtration rate (eGFR) as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation of ≤45 mL/min/1.73 m2 at screening - Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period. - A previous kidney transplant or planned transplant within study treatment period. - Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Subjects with cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been treated with conization or loop electrosurgical excision procedure, and have had a normal repeat PAP are allowed. - Lymphoproliferative disease or previous total lymphoid irradiation. - Severe viral infection (such as CMV, HBV, HCV) within 3 months of screening; or known human immunodeficiency virus infection. - Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid. - Other known clinically significant active medical conditions, such as: - Severe cardiovascular disease including congestive heart failure, history of cardiac dysrhythmia or congenital long QT syndrome. QTcF (QT interval duration corrected for heart rate using method of Fridericia) exceeding 480 msec in the presence of a normal QRS interval (<110 msec) at time of screening will result in exclusion. - Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or bilirubin greater than 2.5 times the upper limit of normal) at screening and confirmed before enrollment. - Chronic obstructive pulmonary disease or asthma requiring oral steroids. - Bone marrow insufficiency unrelated to active SLE (according to Investigator judgment) with white blood cell count <2,500/mm3; absolute neutrophil count <1.3 × 103/μL; thrombocytopenia (platelet count <50,000/mm3). - Active bleeding disorders. - Current infection requiring IV antibiotics. |
Результат
Заходи первинного результату
1. Number of patients achieving identified biomarkers and the number of these patients who go on to achieve week 24 complete remission. [24 weeks]
Заходи вторинного результату
1. The number of subjects achieving complete remission at 24 weeks. [24 weeks]
2. Number of patients achieving identified biomarkers and the number of these patients who go on to achieve week 48 complete remission. [48 weeks]
